First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
Thesis: TELA Bio: the story is balanced — Quarterly revenue growth rate and guidance - market expects 15-25% growth to justify valuation; misses trigger sharp…
★ Analysts see FY2027 revenue reaching $96M — +10.4% growth in a single year.
What Moves the Stock
1Quarterly revenue growth rate and guidance - market expects 15-25% growth to justify valuation; misses trigger sharp selloffs as seen in recent -70% annual decline
2Sales force productivity metrics - revenue per rep and new account additions signal commercial execution and market penetration velocity
3Clinical data releases and surgeon adoption trends - peer-reviewed publications, registry data, and KOL endorsements drive credibility in competitive hernia market
4Cash runway and financing events - with negative $20M+ annual cash burn, dilutive equity raises or debt financings create significant overhang
5Reimbursement developments - CMS and private payer coverage decisions for biologic mesh products affect addressable market and pricing power
6OviTex hernia repair products (estimated 70-80% of revenue) - reinforced biologic scaffolds for ventral/incisional hernia repair
7OviTex PRS products (estimated 15-25%) - plastic and reconstructive surgery applications including breast reconstruction
8International sales (estimated 5-10%) - primarily European markets through direct and distributor channels
Watch on earnings: Quarterly revenue growth rate (YoY and QoQ) - need sustained 15%+ to support valuation, Gross margin percentage - target 75%+ for mature product economics, Operating cash flow and cash burn rate - critical for assessing dilution timeline.
One Sentence Summary:
TELA Bio: the story is balanced — quarterly revenue growth rate and guidance - market expects 15-25% growth to justify valuation; misses trigger sharp selloffs as seen.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.